ArticleFrontiers in medicine2025
Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are several comorbidities associated with psoriasis, including genetic disorders such as hereditary hemochromatosis, which can lead to organ damage secondary to iron overload. Herein, we report the case of a 38-year-old Chinese man with hereditary hemochromatosis who received secukinumab for the treatment of severe psoriasis. Follow-up after 3 months showed that the patient's lesions had almost resolved and remained well-controlled for 2 years without any reported side effects. Patients with psoriasis and hereditary hemochromatosis have limited treatment options due to the effects of iron overload on the liver, particularly because it may increase the risk of hepatocellular carcinoma. Interleukin-17A (IL-17A) inhibitors, such as the secukinumab used in this case, may benefit these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.